An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19 | Coronavirus (COVID-19) | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Published Online: December 11, 2020. doi:10.1001/jama.2020.24415

Once a month, The Medical Letter provides a previously published article to JAMA to be republished.

Previous Publication: This article was published in The Medical Letter on Drugs and Therapeutics. November 30, 2020;62(1612):185-186. It is reprinted here with permission from ©The Medical Letter Inc.

About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not sell advertising or receive any commercial support. Financial support comes primarily from sales of subscriptions, books, software, continuing education materials, and licenses.

For free sample articles and issues of The Medical Letter, go to www.medicalletter.org/tmlj. The Medical Letter—Because the source matters.

Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President and Executive Editor; Jean-Marie Pflomm, PharmD, Vice President and Editor in Chief

References
1.
FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. Published November 9, 2020. Accessed November 13, 2020. https://bit.ly/2HesBBs
2.
Chen  P , Nirula  A , Heller  B ,  et al; BLAZE-1 Investigators.  SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19.   N Engl J Med. Published online October 28, 2020. doi:10.1056/NEJMoa2029849 PubMedGoogle Scholar
3.
National Institutes of Health (NIH) News Release. Statement—NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. Published October 26, 2020. Accessed November 19, 2020. https://bit.ly/3kM2ZK0
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close